Revolutionizing the efficient use of NGS (Next-Generation Sequencing) in precision diagnostics
Genomill Health is a pioneering precision diagnostics company with a mission to disrupt the use of molecular diagnostic tests – liquid biopsies and beyond. We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® pre-sequencing platform, enabling major improvements in performance and scalability.
Our vision is to become the leading technology company within molecular diagnostics and fundamentally transform the global healthcare.
Our proprietary and patented Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.
It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.
We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.